Mustang Bio, Inc. (MBIO): Price and Financial Metrics
GET POWR RATINGS... FREE!
MBIO Stock Price Chart Interactive Chart >
MBIO Price/Volume Stats
| Current price | $0.69 | 52-week high | $4.06 |
| Prev. close | $0.66 | 52-week low | $0.61 |
| Day low | $0.65 | Volume | 643,600 |
| Day high | $0.69 | Avg. volume | 909,663 |
| 50-day MA | $0.84 | Dividend yield | N/A |
| 200-day MA | $1.67 | Market Cap | 69.27M |
Mustang Bio, Inc. (MBIO) Company Bio
Mustang Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T cell technology. Its lead programs include MB-101 for the treatment of brain cancer that is in Phase I trials; and MB-102, a therapeutic agent in acute myeloid leukemia, which is in Phase I trials. The company was founded in 2015 and is based in New York, New York. Mustang Bio Inc. is a subsidiary of Fortress Biotech, Inc.
Latest MBIO News From Around the Web
Below are the latest news stories about Mustang Bio Inc that investors may wish to consider to help them evaluate MBIO as an investment opportunity.
Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers SymposiumWORCESTER, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that City of Hope Phase 1 clinical trial data on MB-105, a prostate stem cell antigen (“PSCA”) chimeric antigen receptor (“CAR”) T-cell therapy administered systemically to pati |
Mustang Bio Selected as a Bronze Winner in Eighteenth Annual Team Massachusetts Economic Impact AwardsWORCESTER, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced the company was selected as the Bronze winner for the Central region in the Eighteenth Annual Team Massachusetts Economic Impact Awards presented by MassEcon. The awards honor c |
One Mustang Bio, Inc. (NASDAQ:MBIO) insider upped their stake by 25% in the previous yearViewing insider transactions for Mustang Bio, Inc.'s ( NASDAQ:MBIO ) over the last year, we see that insiders were net... |
FDA Holds Mustang Bio's Gene Therapy IND For Compromised Immune System DisorderThe FDA has issued a hold, pending Chemistry, Manufacturing & Controls (CMC) clearance, on Mustang Bio Inc's (NASDAQ: MBIO) Investigational New Drug (IND) application for MB-207 in patients with X-linked severe combined immunodeficiency (XSCID). The application was submitted to initiate a pivotal Phase 2 study to assess MB-207 (lentiviral gene therapy) in patients who have been previously treated with a hematopoietic stem cell transplantation, and for whom re-treatment is indicated. The FDA has |
Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted PatientsWORCESTER, Mass., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has issued a hold, pending Chemistry, Manufacturing and Controls (“CMC”) clearance, on the Company’s Investigational New Drug |
MBIO Price Returns
| 1-mo | -9.40% |
| 3-mo | -23.21% |
| 6-mo | -65.50% |
| 1-year | -79.40% |
| 3-year | -80.29% |
| 5-year | N/A |
| YTD | -58.43% |
| 2021 | -56.14% |
| 2020 | -7.23% |
| 2019 | 38.78% |
| 2018 | -75.48% |
| 2017 | N/A |
Continue Researching MBIO
Want to see what other sources are saying about Mustang Bio Inc's financials and stock price? Try the links below:Mustang Bio Inc (MBIO) Stock Price | Nasdaq
Mustang Bio Inc (MBIO) Stock Quote, History and News - Yahoo Finance
Mustang Bio Inc (MBIO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...